La leucémie myéloïde chronique (LMC) est une pathologie de la cellule souche hématopoïétique caractérisée par la présence de la translocation chromosomique t(9 :22) conduisant à l’expression de la kinase BCR-ABL responsable de la maladie. Un inhibiteur de l’activité de BCR-ABL a été identifié, l’Imatinib (IM). L’IM a révolutionné la prise en charge de la LMC en bloquant sélectivement la croissance des cellules tumorales, conduisant à la rémission des patients. Cependant, une majorité d’entre eux subissent des récidives en cas d’arrêt du traitement, et environ 15% développent des résistances à l’inhibiteur. BCR-ABL active de multiples voies de signalisation parmi lesquelles figurent les facteurs de signalisation STAT5. Nous avons analysé les rôles respectives des deux facteurs STAT5, STAT5A et STAT5B, dans les cellules souches hématopoïétiques normales et de LMC, par une approche d’ARN interférence. Nos observations indiquent que l’activité des deux facteurs STAT5 permet la survie et le maintien à long terme des cellules souches de patients LMC au diagnostic. Nous avons de plus montré qu’indépendamment de son activité transcriptionnelle, STAT5A aide les cellules normales et leucémiques à limiter leur stress oxydatif. Nous avons aussi pu observer que les cellules de patients présentant des résistances secondaires à l’IM, sans mutations ni surexpression de BCR-ABL, manifestent une dépendance caractéristique vis-à-vis de l’activité STAT5A. Pour mieux comprendre les mécanismes d’action des facteurs STAT5, nous avons recherché les gènes cibles de STAT5 par une approche transcriptomique et avons identifié le récepteur tyrosine kinase Axl dont l’expression est augmentée par STAT5A. L’inhibition d’Axl dans les cellules LMC sensibles à l’IM n’a aucun effet sur leur survie, alors qu’elle diminue fortement la survie des cellules LMC résistantes à l’IM. De plus, Axl contrôle le niveau des réactifs oxygénés dans les cellules de patients LMC. Nous avons analysé l’expression d’un des activateurs d’Axl, le ligand Gas6, et avons observé que son expression diminue fortement dans les cellules primaires de LMC par rapport aux contrôles sains. Ces résultats suggèrent que le tandem Gas6/Axl pourrait participer au processus leucémique de la LMC à différents niveaux. De manière globale, nos travaux montrent que les facteurs STAT5 favorisent le maintien des cellules souches de LMC, leur résistance au stress oxydatif et aux traitements thérapeutiques Ces deux dernières activités sont au moins en partie liées à l’activité d’une nouvelle cible de STAT5, le récepteur Axl, par ailleurs déjà impliqué dans la résistance aux traitements thérapeutiques. Les facteurs STAT5 représentent donc des nouvelles cibles thérapeutiques potentielles dans l’éradication de la maladie résiduelle. / The Chronic Myeloid Leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the t(9:22) genetic translocation and expression of the oncogenic tyrosine kinase BCR-ABL . A first BCR-ABL Tyrosine Kinase Inhibitor (TKI), Imatinib (IM), was identified that inhibits proliferation of BCR-ABL expressing hematopoietic cells and leads to disease remission. However, BCR-ABL mRNA remains detectable in the most immature HSCs and discontinuation of IM results in clinical relapse. STAT5 factors play a crucial role in the CML pathogenesis of human primary CML cells. However, the contribution of the two related STAT5 genes, STAT5A and STAT5B, was unknown. We used an RNAinterference based strategy to analyze STAT5A or STAT5B roles in normal and CML cells. We showed that STAT5A/5B double knock-down (KD) triggers normal and CML cell apoptosis and suppressed long-term clonogenic potential of immature hematopoietic stem and progenitor cells known to be resistant to TKI treatment and responsible for residual disease. STAT5A loss alone was ineffective at impairing growth of both normal and CML cells under standard conditions. In contrast, STAT5A loss was sufficient to enhance Reactive Oxygen Species (ROS) which correlated with enhanced DNA damages in both normal and leukemic cells. We reported that STAT5A regulates oxidative stress through unconventional mechanisms, in a non-transcriptional-dependent manner. We further showed that, in contrast to primary cells at diagnosis, IM-resistant cells exhibited enhanced STAT5A dependence, by being sensitive to STAT5A single KD. To investigate the molecular basis of STAT5A activity in TKI-resistance and oxidative stress, we performed a transcriptomic analysis of STAT5 regulated genes. We identified Axl, which encodes a receptor tyrosine kinase, recently shown to be crucial in TKI-resistant CML cells. Specifically, Axl expression is enhanced by STAT5A. We investigated the role of Axl and we found that Axl KD did not affect survival of IM-sensitive CML cells. However, Axl KD decreased survival of IM-resistant cells, miming the activity of STAT5A. Moreover, Axl loss increased ROS levels in CML cells, promoting STAT5A anti-oxidant activity. We further sought to determine the expression of the Axl ligand, Gas6. Gas6 expression is dramatically reduced in CML primary cells at diagnosis compared to healthy cells. The strong and consistent down-regulation of Gas6 in CML cells suggested a possible role in the pathophysiology. Collectively, our findings highlight the pro-survival, stress protection and drug resistance roles of STAT5 factors, providing new understanding for medical treatment of CML patients. We suggest that STAT5A acts in synergy with Axl to face exogenous insults and propose a new mechanism by which CML cells increase their proliferation and reduce their motility by down-regulating Gas6 expression.

No description available.

Cancer cells have been known for some time to have very different metabolismas compared to that of normal non proliferating cells. As metabolism is involvedin almost every aspect of cell function, there has been a recent resurgence ofinterest in inhibiting cancer metabolism as a therapeutic strategy. Inhibitors thatspecifically target altered metabolic components in cancer cells are being developedas antiproliferative agents. However, many such inhibitors have not progressedinto the clinic due to limited efficacy either in vitro or in vivo. In this study weexplore the hypothesis that this is often due to the robustness of the metabolicnetwork and the differences between individual cancer cell lines in their metaboliccharacteristics. We take a systems biology approach. We investigate the cellular bioenergetic profiles of a panel of five non-small celllung cancer cell lines before and after treatment with a novel inhibitor of theglutaminase-1 (GLS1) enzyme. Additionally, we explore the effects of this inhibitoron intracellular metabolism of these cell lines as well as on the uptake and secretionof glucose, lactate and amino acids. To be able to do the latter robustly, wehad to modify the experimental assay considerably from procedures that seemto be standard in the literature; using these earlier procedures the metabolicenvironment of the cells was highly variable, leading to misleading results onthe metabolic effects of the inhibitor. We reduced cell density, altered mediumvolume and changed the time-window of the assay. This led to the cells growingexponentially, appearing indifferent to the few remaining changes. In this newassay, the metabolic effects of the glutaminase inhibitor became robust. One of the most significant results of this study is the metabolic heterogeneitydisplayed across the cell line panel under basal conditions. Differences in themetabolic functioning of the cell lines were observed in terms of both theirbioenergetic and metabolic profile. The amount of respiration attributed tooxidative phosphorylation differed between cell lines and respiratory capacity wasattenuated in most cells. However, the rate of glycolysis was similar betweencell lines in this assay. These results suggest that the Warburg effect arisesthrough a greater diversity of mechanisms than traditionally assumed, involvingvarious combinations of changes in the expression of glycolytic and mitochondrialmetabolic enzymes. The effects of GLS1 inhibition on cellular bioenergetics and metabolism alsodiffered between cell lines, even between resistant cell lines, indicating that theremay also be a diversity of resistance mechanisms. The metabolomic response ofcell lines to treatment suggests potential resistance mechanisms through metabolicadaptation or through the prior differences in the metabolic function of resistantcell lines. Part of the metabolome response to GLS1 inhibition was quite specificfor sensitive cells, with high concentrations of IMP as the strongest marker. Our results suggest that the metabolome is a significant player in what determinesthe response of cells to metabolic inhibitors, that its responses differ between cancercells, that responses are not beyond systems understanding, and that thereforethe metabolome should be taken into account in the design of and therapy withanti-cancer drugs.

Notre projet vise à déterminer la structure 3D du transporteur BmrA de Bacillus subtilis. La protéine a été purifiée dans six détergents différents. L'utilisation de foscholine 12, a conduit à cristalliser OmpF, une porine de la membrane externe d'E. coli. Nous montrons que les conditions de cristallisation influencent directement l'empilement cristallin d'OmpF. Le protocole de purification de BmrA, optimisé en utilisant du triton X100 à l'extraction puis un mélange β-D-dodecyl maltoside-cholate pour les étapes chromatographiques nous a permis d'obtenir à 4°C des cristaux, pour lesquels nous avons vérifié qu'ils sont constitués de BmrA. Ces cristaux ont permis d'obtenir un jeu complet jusqu'à 7 Å. Ces données de diffraction constituent une avancée significative pour résoudre à court terme la structure 3D de BmrA. Nous avons développé une nouvelle méthode de dosage des détergents qui est basée sur la détermination par spectrométrie de masse de type MALDI du ratio d'isotopes deutérés/ protonés. La méthode a été validée avec la FC12, le DDM, le β-OG, le LMNG, le CHAPS, le cholate et des détergents calix[4]aréniques, en mesurant la concentration de ces détergents dans différentes conditions d'extraction/purification, de concentration, dialyse et gel filtration, de différentes protéines membranaires. Cette méthode nous a permis (i) d'estimer la taille de la ceinture de détergent associée à BmrA et d'autres protéines membranaires (ii) de moduler cette taille en fonction de mélange de détergents et (iii) d'apporter des informations sur le comportement des complexes protéine-détergent / Our project aims to determine the 3D structure of BmrA from Bacillus subtilis. The protein was purified in six different detergents. Using foscholine 12, led to crystallize OmpF, an outer membrane porin of E. coli. We show that the crystallization conditions directly influence the crystal packing of OmpF. The BmrA purification protocol optimized by using Triton X100 at the extraction and a mixture β-D-dodecyl-maltoside cholate for chromatographic steps allowed us to get to 4°C crystals, for which we verified they consist of BmrA. These crystals have yielded full data to 7 Å. These diffraction data are a significant advance in the short term to resolve the 3D structure of BmrA. We have developed a new detergents dosage assay which is based on the determination by MALDI-type mass ratio of deuterated isotopes / protonated. The method was validated with the FC12, the DDM, the β-OG, the LMNG, CHAPS, cholate detergents and calix [4] aréniques by measuring the concentration of these detergents in different conditions of extraction/ purification, concentration, dialysis and gel filtration, of different membrane proteins. This method allowed us (i) to estimate the size of the detergent belt associated to BmrA and other membrane proteins (ii) to modulate this size in terms of the detergent mixture and (iii) to provide information on the behavior of complex protein-detergent

Infection with Helicobacter pylori has been associated with the pathogenesis of numerous stomach and gastroduodenal diseases that pose threats to public health. Eradicaftion of this pathogen is a global challenge due to its alarming rate of multidrug resistance. Consequently, to find an alternative treatment, the search is increasingly focused on new antimicrobial product from natural sources including honey. Honey has been used as medicine in several cultures since ancient time due to its enormous biomedical activities. Its beneficial qualities have been endorsed to its antimicrobial, antioxidant, anti-inflammatory properties added to its phytocomponents. In this study, the anti-H. pylori activity of South African honeys and their solvent extracts as well as the phytochemicals present in the two most active honeys were evaluated. Agar well diffusion test was used to investigate the antimicrobial activity of six honey varieties obtained from different locations in the country. Subsequently, the honeys were extracted with four organic solvents viz n-hexane, diethyl ether, chloroform and ethyl acetate employed in order of increasing polarity. The antibacterial activity of the different solvent extracts of each honey was evaluated by agar well diffusion; broth micro dilution and time kill assays. Different chromatographic techniques (Thin layer & column chromatography) were employed to enumerate the phytochemical constituents in the most active solvent extracts of Pure Honey (PH) and Champagne Royal Train (CRT); and were identified by gas-chromatography linked mass-spectrometry. Linalool pure compound was equally evaluated for anti-H. pylori activity in a bid to trace the antibacterial agent among the variety of compounds identified. Data were analyzed by One-way ANOVA test at 95% confidence interval. Crude honeys and their solvent extracts demonstrated potent anti-H. pylori activity with zone diameter that ranged from [16.0mm (crude) to 22.2mm (extract)] and percentage susceptibilities of test isolates between 73.3% (crude) and 93.3% (extract). The chloroform extracts of PH and CRT were most active with MIC50 in the ranges 0.01- viii 10%v/v and 0.625-10%v/v respectively, not significantly different from amoxicillin (P> 0.05); and efficient bactericidal activity (100% bacterial cells killed) at 1/2MIC and 4xMIC over different time intervals, 36-72hrs and 18-72hrs respectively. The appearance of bands on the thin layer chromatography (TLC) chromatogram spotted with the chloroform extracts of PH and CRT; and developed with hexane: ethyl acetate: acetic acid (HEA) and methanol: acetic acid: water (MAAW) solvent systems indicated the presence of compounds. Purification of the compounds contained in these extracts over silica gel column yielded numerous fractions which were evaluated for antibacterial activity and purity. PHF5 was the most active fraction with a mean MIC50 value of 1.25mg/mL. Volatile compounds belonging to different known chemical families in honey were identified in all the active fractions obtained from PH. Conversely, only four compounds were identified in the active fractions obtained from CRT hence the non volatile constituents could be of prime relevance with respect to antibacterial activity of this honey. Of novelty was the presence of thiophene and N-methyl-D3-azirdine compounds, essential precursors used for the synthesis of natural products and pharmaceuticals with vital biomedical properties. Linalool demonstrated potent inhibitory (MIC95, 0.002- 0.0313mg/mL) and bactericidal activity (0.0039-0.313mg/mL) against the test isolates. On the other hand, a significant difference was recorded (P < 0.05) in comparing the activity of linalool compound to the fractions. PH could serve as a good economic source of bioactive compounds which could be employed as template for the synthesis of novel anti-H. pylori drugs. However, further studies are needed to determine the non volatile active ingredients in PH and CRT as well as toxicological testing

Le paludisme, maladie parasitaire et vectorielle, sévissant principalement dans les zones intertropicales où vit près de 40% de la population mondiale, reste un problème majeur en santé publique. Les cinq espèces de Plasmodium connues infectées le paludisme chez l'homme sont présentes au Cambodge, qui est reconnu comme l'épicentre de l'émergence de souches de P. falciparum multi-résistantes (chloroquine, sulfadoxine- pyriméthamine, méfloquine, artémisinine), pouvant entraver les progrès accomplis depuis plus d'une décennie. Le travail de thèse intitulé « Approche génomique et bio-informatique de l'émergence et de la diffusion des résistances chez Plasmodium au Cambodge » avait pour objectif de développer de nouveaux outils moléculaires et biologiques pour 1) une meilleure compréhension de l'impact des stratégies mises en place pour lutter contre le paludisme à P. falciparum sur les autres espèces de Plasmodium, 2) la mise en place d'outils biologique et moléculaire, permettant de mieux définir l'épidémiologie des parasites résistants, en particulier la résistance à la quinine et aux dérivés de l'artémisinine, 3) l'étude et la définition des sous-populations parasitaires circulant au Cambodge afin d'estimer les risques associés à la diffusion de la résistance à l'artémisinine. Cette thèse a été réalisée dans l'Unité d'Epidémiologie Moléculaire du Paludisme à l'Institut Pasteur du Cambodge (IPC) sous la codirection du Dr. Didier Ménard (Chef de laboratoire à l'IP) et du Pr. Emmanuel Cornillot (Professeur à l'Université Montpellier I). Le premier objectif visait à étudier l'impact de la pression médicamenteuse sur la dynamique d'évolution des populations parasitaires. Nous avons d'abord évalué le polymorphisme des gènes associés à la résistance à la pyriméthamine (gène dhfr, dihydrofolate reductase) chez Plasmodium malariae et Plasmodium ovale (article 1 et manuscrit en préparation1), et le polymorphisme du gène mdr-1 (multidrug resistance 1) associé à la résistance à la mefloquine chez P. vivax (article 2). De plus, en collaboration avec l'Institut Pasteur de Madagascar, nous avons étudié le lien pouvant exister entre le polymorphisme du gène candidat Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) et la résistance (clinique et in vitro) de P. falciparum à la quinine (articles 3 et 4).Le deuxième objectif s'est interessé au développement d'outils biologiques et moléculaires permettant d'évaluer la résistance des souches de P. falciparum aux dérivés de l'artémisinine. Les 3 articles présentés (articles 5, 6 et 7) decrivent la méthodologie d'approche originale utilisée associant la génomique, la biologie, la clinique et l'épidémiologie, qui a permis d'aboutir à la découverte d'un marqueur moléculaire (mutations au sein du gène Kelch 13) fiable pour identifier les souches résistantes aux dérivés de l'artémisinine.Le dernier objectif était consacré au développement de la technique PCR-LDR-FMA appliqué à la détection d'un panel de 24 SNPs permettant de caractériser par un « barcode » chaque isolat de P. falciparum. Cette technique couplée avec une analyse bio-informatique et statistique des données nous a permis d'étudier et de définir la structuration des populations parasitaires circulant au Cambodge afin d'estimer les zones à risque de diffusion de la résistance à l'artémisinine (manuscrit en préparation 2).A travers ce travail de thèse, nous nous sommes efforcés de montrer la puissance des techniques de biologie moléculaire disponibles couplées avec des approches génomique et bio-informatique pour améliorer notre compréhension de la dynamique d'évolution des populations parasitaires. Ce travail s'est essentiellement concentré sur les phénomènes liés à l'émergence et de la diffusion des parasites résistants aux antipaludiques, le but final de ce travail étant d'améliorer les stratégies de lutte mises en place pour atteindre l'ambitieux objectif d'élimination du paludisme. / Malaria, a protozoan vector-borne disease, is mainly prevalent in tropical areas, where nearly 40% of the world population is residing and remains one of the most concerns for public health worldwide. In Cambodia, the five Plasmodium species known to cause malaria in humans are present. The main feature of this country is that it is recognized as the epicenter of the emergence of multi-resistant P. falciparum parasites (to chloroquine, sulfadoxine-pyrimethamine, mefloquine, and artemisinin), a very significant menace to public health in the Mekong region that could impact the worldwide strategy to fight malaria. The thesis presented here, entitled “Genomics and Bioinformatics in the emergence and spread of resistant Plasmodium in Cambodia” aimed to develop new molecular and biological tools for:1) improving our understanding of the collateral impact of the strategies implemented to fight against falciparum malaria on the other Plasmodium species; 2) defining the molecular epidemiology of antimalarial resistant parasites, especially resistance to quinine and artemisinin derivatives;3) studying and defining the structure of P. falciparum parasite populations circulating in Cambodia to estimate areas at risk of spread of artemisinin resistance, using genomic approaches and bioinformatics. This thesis was carried out in the Malaria Molecular Epidemiology Unit at Pasteur Institute in Cambodia (IPC) under the co-direction of Dr. Didier Ménard (Head of the Unit, IP) and Pr. Emmanuel Cornillot (Professor, University of Montpellier I). The first objective of this work was to study the impact of drug used to treat falciparum malaria on the dynamics of other Plasmodium species. In a first step, we evaluated the polymorphism in gene associated to pyrimethamine resistance (dhfr gene, dihydrofolate reductase) in Plasmodium malariae and in Plasmodium ovale (article 1 and manuscript in preparation 1) and the polymorphism in mdr-1 gene (multidrug resistance 1 gene) associated to mefloquine resistance in P. vivax (article 2). Secondly, in collaboration with Pasteur Institute in Madagascar, we investigated the association between the polymorphism in Plasmodium falciparum Na + / H + exchanger gene (Pfnhe-1) and quinine resistance defined either by clinical or in vitro phenotypes (articles 3 and 4). The second objective was focused on the development of novel biological and molecular tools to assess the resistance of P. falciparum to artemisinin derivatives. The three papers presented (articles 5, 6 and 7) describe an original approach combining genomics, biological, clinical and epidemiological studies, which lead to the discovery of a molecular marker (mutations Kelch 13 gene) associated to artemisinin resistance.The third and final objective was devoted to the development of the PCR-LDR-FMA technology applied to the detection of a panel of 24 SNPs to characterize a "barcode" of P. falciparum isolates. This technic coupled with bioinformatics and statistical analysis allowed us to study and define the structure of the parasite populations circulating in Cambodia for estimating areas at risk of spread of artemisinin resistance (manuscript in preparation 2). Through this work, we have tried to show the usefulness of available molecular biology methods coupled with genomic and bioinformatics approaches to improve our understanding of the dynamics of the malaria parasite populations. This work has been mainly focused on the emergence and spread of antimalarial resistant parasites, keeping in mind that the ultimate goal of this work was to improve strategies implemented to achieve the ambitious goal of malaria elimination.

Orientadores: Patrícia Moriel, Carlos Emílio Levy / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-26T14:28:55Z (GMT). No. of bitstreams: 1 Mattos_KarenPradoHerzer_M.pdf: 1543498 bytes, checksum: 9d1f9328148bdfe74a6e65854c319426 (MD5) Previous issue date: 2014 / Resumo: As Infecções de Trato Urinário (ITUs) são definidas como colonizações microbianas com invasão tecidual de qualquer parte do trato urinário, desde a uretra até os rins, considerada a doença infecciosa extra intestinal de origem comunitária mais comum em todo mundo. As ITUs em sua maioria são causadas por bactérias Gram-negativas, sendo a Escherichia coli o micro-organismo invasor mais comum, isolado em cerca de 80% a 90% das infecções agudas de origem comunitária. Neste início de terceiro milênio, a resistência bacteriana é um dos desafios globais de saúde pública a ser enfrentado e sabe-se que, a intensidade de exposição ao antimicrobiano é um importante parâmetro relacionado à seleção e à manutenção de bactérias resistentes. Em 2010 o Brasil vivia uma situação na qual estavam sendo observados vários focos de infecções hospitalares causadas por micro-organismos multirresistentes como a Klebsiella pneumoniae produtoras de carbapenemase (KPC). Em função do preocupante cenário, em 2010 foi implantada a Resolução da Diretoria Colegiada (RDC) nº 44 da Agência Nacional de Vigilância Sanitária (ANVISA) que possui, dentre outros objetivos, a diminuição da resistência bacteriana aos antimicrobianos. Objetivo: Estudar o perfil de resistência de bactérias Gram-negativas relacionadas às ITUs de origem comunitária e analisar a influência da legislação atuante no controle de venda de antimicrobianos. Métodos: População de pacientes de demanda espontânea aos hospitais da Universidade Estadual de Campinas entre 2009 e 2013 com hipótese-diagnóstica de ITU de origem comunitária, de ambos os sexos, independente de raça e idade. As amostras de urina dos pacientes foram encaminhadas ao Laboratório de Microbiologia Clínica da instituição e foram incluídas no estudo as uroculturas com resultado positivo para os agentes etiológicos Escherichia coli, Klebsiella pneumoniae e Proteus mirabilis. Os antimicrobianos foram agrupados em 5 classes: Aminoglicosídeos, Fluorquinolonas, Sulfonamidas, Beta-lactâmicos e Nitrofurano . Foi realizada análise estatística descritiva e o nível de significância adotado foi de 5%. Resultados e discussão: Os dados demográficos demonstraram prevalência média de 75% de ITU's em mulheres. A idade média dos casos de ITU foi de 40 ± 1,8 anos. A E. coli foi o patógeno mais frequente (83%) nos exames de urocultura para casos de ITU. O relatório estatístico não apontou diferenças significantes entre a variação dos percentuais de resistência bacteriana para E. coli e P. mirabilis, além de não apontar uma tendência linear. Apenas a K. pneumoniae apresentou resultado estatístico significante na análise geral quando foi observado aumento das taxas de resistência e tendência linear crescente. A E. coli apresentou queda do percentual de resistência bacteriana e tendência linear decrescente com relação às fluorquinolonas. Estudo de 2013 da Universidade de São Paulo analisou o consumo extra hospitalar de antimicrobianos e observou queda de 7% do consumo geral, além de queda de 28% da venda de norfloxacino, o que suporta nossos resultados. Conclusão: Sugere-se que a RDC nº 44/2010 influenciou na queda das taxas de resistência bacteriana entre a classe das fluorquinolonas, principalmente o ciprofloxacino, para ITU¿s de origem comunitária / Abstract: Introduction: Community-acquired urinary tract infections (UTIs) are extra intestinal infectious diseases, causing microbial colonization and tissue invasion in the urinary tract. Gram-negative bacteria, especially Escherichia coli, are the most common invasive microorganisms causing UTIs; they are isolated in 80%¿90% of acute infections of community origin. Bacterial resistance is currently a global public health challenge. The intensity of bacterial exposure to antimicrobials is an important parameter affecting the selection and maintenance of resistant bacteria. In 2010, Brazil witnessed several outbreaks of nosocomial infections caused by multidrug-resistant microorganisms such as Klebsiella pneumoniae carbapenemase (KPC). Collegiate Board Resolution (CBR) no. 44 was introduced by the National Health Surveillance Agency with the goal of reducing bacterial resistance to antimicrobials. Objectives: To study the resistance profile of gram-negative bacteria causing community-acquired UTIs and to analyze the influence of the legislation promoting active control of the sale of antimicrobials. Methods: Patients of different gender, ethnicity, and age, admitted at the State University of Campinas Hospital between 2009 and 2013, with a diagnosis of suspected community-acquired UTI were included in the study Patients with urine cultures positive for Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis were included in the study. The antimicrobial classes used were aminoglycosides, fluoroquinolones, sulfonamides, beta-lactams, and nitrofuran. Descriptive statistical analysis was performed, and the level of significance was set at 5%. Results and Discussion: Demographic data showed the average prevalence of UTIs among women to be 75%. The average age of the affected individuals was 40 ± 1.8 years. E. coli was the most common pathogen (83%) detected in urine culture tests for UTI cases. The percentage of variation of bacterial resistance was not significant between E. coli and P. mirabilis and did not indicate a linear trend. Only K. pneumoniae showed a statistically significant result in the overall analysis, showing increasing rates of resistance and an increasing linear trend. E. coli demonstrated a decrease in the percentage of bacterial resistance and a decreasing linear trend in fluoroquinolone resistance. The 2013 study from the University of Sao Paulo discussed the extra-hospital antimicrobial consumption, and observed a 7% decline in overall consumption and a 28% decline in the sale of norfloxacin, which supports our results. Conclusion: It is suggested that CBR nº 44/2010 influenced the decline in the rate of bacterial resistance towards fluoroquinolones, especially ciprofloxacinin community-acquired UTIs / Mestrado / Ciencias Biomedicas / Mestra em Ciências Médicas

O objetivo principal deste estudo foi avaliar a frequência de cepas do HBV com mutações de resistência aos análogos nucleos(t)ídeos (AN) utilizados no tratamento da hepatite B entre indivíduos cronicamente infectados, não submetidos a tratamento, procedentes de diferentes regiões do Brasil. Além disso, foram avaliadas a presença de mutações que alteram a antigenicidade do HBsAg promovendo escape dos anticorpos anti-HBs; mutações nos genes pré-core/core e a associação dos diferentes subgenótipos com as mutações encontradas e características demográficas e laboratoriais dos pacientes. Foram incluídas 779 amostras de soro de pacientes com infecção crônica pelo HBV e virgens de tratamento com AN ou interferon, as quais foram coletadas no período de 2006 a 2011. Os pacientes eram procedentes dos seguintes estados brasileiros: Pará, Maranhão, Bahia, Minas Gerais, São Paulo, Paraná e Rio Grande do Sul. O DNA do HBV foi extraído das amostras de soro utilizando o Kit QIAamp DNA Blood Mini Kit (Qiagen) e posteriormente foi realizada a amplificação das regiões S/polimerase (S/P) e pré-core/core (PCC) do genoma viral por nested PCR. O fragmento amplificado foi submetido a sequenciamento direto em sequenciador automático de DNA (ABI 3500) e as sequências obtidas foram analisadas para identificação dos genótipos e subgenótipos do HBV, pesquisa de mutações na polimerase, no HBsAg e nos genes pré-core/core. A região S/Pol foi amplificada e sequenciada com sucesso em 702 amostras, as quais foram incluídas para atender aos objetivos deste estudo. Entre as 702 amostras analisadas sete genótipos e 12 subgenótipos do HBV foram identificados. O subgenótipo A1 foi o mais frequente (63,7%, 447/702), seguido pelo HBV/D3 (14,5%, 102/702). Os demais genótipos e subgenótipos encontrados e suas frequências foram as seguintes: A2 (3,3%, 23/702), A3 (0,1%, 1/702), B1 (0,1%, 1/702), B2 (0,1%, 1/702), C2 (0,9%, 6/702), D1 (0,9%, 6/702), D2 (4,6%, 32/702), D4 (5,1%, 36/702), D com subgenótipo não identificado (0,7%, 5/702), E (0,6%, 4/702), F2a (4,6%, 32/702), F4 (0,4%, 3/702), e G (0,4%, 3/702). Cepas do HBV com mutações de resistência (rtS202G, rtM204V/I, rtA194T, rtM250I, rtA181T/S, rtT184S) associadas ou não a mutações compensatórias (rtL80I, rtV173L, rtL180M, rtV207I) foram identificadas em 1,6% (11/702) das amostras analisadas. Cepas com mutações potencialmente associadas com resistência ao adefovir (rtS85A, rtL217R, rtI233V, rtN238T, rtN238D, rtN248H, rtV214A,e rtQ215S) ou ao entecavir (rtS219A) foram identificadas em 7,7% (54/702) e 2,6% (16/702) dos pacientes, respectivamente. Cinquenta e sete (8,5%) amostras apresentaram cepas do HBV com mutações na principal região hidrofílica do HBsAg previamente relacionadas com escape dos anticorpos anti-HBs ou com prejuízo na secreção do HBsAg. Foram feitas análises estatísticas para avaliar a correlação entre os subgenótipos do HBV mais frequentes na casuística (A1, A2, D1, D2, D3, D4 e F2a) e a presença de mutações nos genes PCC. Dentre as mutações nos genes PCC associadas com redução ou falha na expressão do HBeAg, as mutações A1762T/T1764A estiveram associadas aos subgenótipos A1 e F2a; G1862T e mutações nas posições 1809-1812 ao subgenótipo A1; G1896A e/ou G1899A aos subgenótipos D2, D3 e D4. Mutações associadas com evolução da doença foram detectadas e entre essas as mutações C1766T e T1768A estiveram associadas aos subgenótipos A1 e F2a, e a mutação G1888A foi associada ao subgenótipo A1. As cepas do HBV que circulam nas diferentes regiões brasileiras estudadas apresentam grande variabilidade genética e a distribuição dos genótipos e subgenótipos reflete a formação histórica de cada região e do fluxo migratório mais recente. A frequência de cepas do HBV com mutações de resistência aos AN circulando entre pacientes virgens de tratamento com esses medicamentos nas diferentes regiões do Brasil estudadas é baixa, sendo que o perfil de mutações que confere resistência total à lamivudina e parcial ao entecavir parece ser o mais disseminado. Embora tenham sido detectados casos de infecção com cepas do HBV portando mutações com grande impacto na antigenicidade dessa proteína todas as amostras apresentaram HBsAg detectável. Pacientes com HBeAg negativo foram mais frequentes na casuística estudada, independente do subgenótipo. As mutações encontradas nos genes PCC sugerem que há perfis de mutações diferentes envolvidos na negatividade do HBeAg para cada subgenótipo / The main aim of this study was to evaluate the frequency of HBV strains harboring mutations that confer resistance to nucleos(t)ide analogues (NA) used to hepatitis B treatment among treatment-naïve patients with chronic hepatitis B from different Brazilian region. Furthermore, we evaluated the presence of mutations that alter the antigenicity of HBsAg causing anti-HBs escape; mutations in genes pre-core/core and the association of different subgenotypes with the mutations detected and demographic and laboratory characteristics of the patients. Serum samples from 779 treatment-naïve patients with chronic HBV infection were included in this study. The samples were collected between 2006 to 2011 and the patients were from the following states: Pará, Maranhão, Bahia, Minas Gerais, São Paulo, Paraná and Rio Grande do Sul. HBV DNA was extracted from serum samples using the QIAamp DNA Blood Mini Kit (Qiagen) and amplification of S/polymerase (S/Pol) and pre-core/core (PCC) regions were performed by nested PCR. The amplified PCR products were submitted to sequencing in an automatic DNA sequencer (ABI 3500). The sequences obtained were analyzed to classify HBV genotypes/subgenotypes and to analyze the presence of mutations. S/Pol region was amplified and sequenced successfully from 702 samples, which were included in this study. Among these 702 samples, seven genotypes and 12 subgenotypes have been identified. HBV subgenotype A1 was the most frequent (63.7%, 447/702), followed by HBV/D3 (14.5%; 102/ 702). The remaining genotypes and subgenotypes identified and their frequencies were as follows: A2 (3.3%, 23/702), A3 (0.1%, 1/702), B1 (0.1%, 1/702), B2 (0.1%, 1/702), C2 (0.9%, 6/702), D1 (0.9%, 6/702), D2 (4.6%, 32/702), D4 (5.1%, 36/702), D unclassified subgenotype (0.7%, 5/702), E (0.6%, 4/702), F2a (4.6%, 32/702), F4 (0.4%, 3/702), and G (0.4%, 3/702). HBV strains harboring mutations conferring NA resistance alone (rtS202G, rtM204V/I, rtA194T, rtM250I, rtA181T/S, rtT184S) or combined with compensatory mutations (rtL80I, rtV173L, rtL180M, rtV207I) were identified in 1.6% (11/702) of the patients. Isolates harboring mutations potentially associated with adefovir resistance (rtS85A, rtL217R, rtI233V, rtN238T, rtN238D, rtN248H, rtV214A, and rtQ215S) or entecavir resistance (rtS219A) were identified in 7.7% (54/702) and 2.6% (16/702) of the patients, respectively. HBV with HBsAg mutations previous related with anti-HBs escape or impaired secretion were detected in 8.5% (57/702) of the samples. Statistical analyzes were performed to assess the correlation between the more frequent HBV subgenotypes found in this study (A1, A2, D1, D2, D3, D4 and F2a ) and mutations in PCC genes. Among the mutations found in these genes that were associated with reduction or failure in HBeAg synthesis, A1762T/T1764A mutations were associated to subgenotypes A1 and F2a; G1862T and mutations at positions 1809-1812 to subgenotype A1; G1896A and/or G1899A to subgenotypes D2, D3 and D4. Other mutations associated with disease progression were found: C1766T and T1768A mutations were associated with subgenotypes A1 and F2a, and the G1888A mutation was associated with subgenotype A1. HBV strains circulating in different Brazilian regions studied showed high genetic variability and distribution of genotypes and subgenotypes reflects the population formation history of each region and the occurrence of recent events of migration. The frequency of HBV strains with NA resistance mutations circulating among treatment-naive patients in different regions of Brazil studied is low and the profile of mutations that confer total resistance to lamivudine and partial resistance to entecavir is more widespread. Although some cases of infection have been detected with HBV strains carrying mutations associated with major impact on the antigenicity of this protein, all samples had detectable HBsAg. HBeAg negative cases were more frequent in the studied population, regardless of subgenotype. Different pattern of mutations were found in PCC genes, suggesting that different mechanisms are involved in HBeAg negativity for each subgenotype

INTRODUÇÃO: Racional: A alta atividade plaquetária residual (AAPR) em uso do AAS é considerada um fator de mau prognóstico em portadores de síndrome isquêmica miocárdica instável (SIMI). Adicionalmente, as taxas de prevalência de AAPR verificadas em diferentes estudos realizados na fase aguda das SIMI são consideradas elevadas em relação às verificadas em portadores de doença arterial coronariana estável. Todavia, não está bem demostrado se essa elevada prevalência de AAPR diagnosticada na fase aguda das SIMI representa um fenômeno transitório, desaparecendo na fase tardia, ou se é um estado permanente, independente da fase aguda. MÉTODOS: O objetivo primário do presente estudo foi o de comparar, em pacientes com SIMI sem supradesnível do segmento ST, a resposta antiplaquetária ao AAS nas fases aguda e tardia na mesma população. Foram incluídos 70 pacientes com SIMI sem supradesnível de ST (77% com angina instável e 22% com IAM sem supra de ST), com idade média de 64,97 anos, sendo 54% do sexo feminino, todos em uso de AAS na dose de 100 a 200mg por pelo menos sete dias anteriores à inclusão. Os pacientes foram submetidos a cinco testes de agregação plaquetária na fase aguda, e os mesmos testes foram repetidos na fase tardia, três meses depois: VerifyNowAspirin®, agregometria de sangue total (AST) com ácido aracdônico (AA) e colágeno, tromboxane B2 sérico, PFA-100. RESULTADOS: De acordo com os testes COX-1 específicos (VFN e AST com AA), a AAPR em uso do AAS foi mais prevalente na fase aguda das SIMI do que na fase tardia (VFN: 32,1% versus 16%, p=0,049; e AST com AA: 31,4% versus 12,8%, p=0,015). Os testes não específicos (AST com colágeno, PFA) e o teste bioquímico não conseguiram demonstrar diferenças entre as fases. A correlação entre os cinco testes realizados foi considerada fraca ou moderada. CONCLUSÃO: A alta prevalência de AAPR, apesar do uso da AAS durante as SIMI, reflete mais provavelmente um estado de hiper-reatividade plaquetária transitória, que se reverte na fase crônica e estável da DAC, de acordo com os testes COX-1 específicos. A correlação entre os testes plaquetários foi apenas moderada nos dois cenários / BACKGROUND: The high residual platelet activity (HRPA) in response to acetylsalicilic acid (ASA) is considered a poor prognostic factor in patients with acute coronary syndromes (ACS). Additionally, the HRPA prevalence rates reported by different studies in ACS patients are considered high compared to those reported in patients with stable coronary artery disease. However, it is not well demonstrated whether this high HRPA prevalence diagnosed during the acute phase represents a transient phenomenon, disappearing in the late phase, or if it is a permanent state, independent of the acute phase. The aim of this study was to compare platelet aggregation in response to ASA during the ACS acute phase with the platelet aggregation in chronic stable phase. METHODS: Inclusion of patients with non ST ACS who were on aspirin at a dose of 100mg to 200mg per day for at least seven days prior to inclusion. We conducted five tests of platelet aggregation in the first 48 hours and repeated them three months later: VerifyNow Aspirin® (VFN), Whole Blood aggregometry (WBA) with arachidonic acid (AA) and collagen, thromboxane B2, PFA-100®. We analyzed 70 patients (77% with unstable angina and 22% with non ST AMI), mean age 64.97 years, 54% female. According to the COX-1 specific tests, the HRPA was more frequent in the acute phase than in the chronic phase (VerifyNowAspirin®: 31.4% versus 12.8%, p=0.015; and WBA with AA: 32.1% versus 16%, p=0.049; respectively). The non specific tests (AST with collagen and PFA) and the biochemical test sTXB2 failed to show differences between the phases. The correlation between the five tests was considered weak or moderate. CONCLUSION: The high prevalence of RPA despite the use of aspirin during the acute phase of the SCA most likely reflects a state of transient platelet hyperreactivity, which is reversed in the chronic phase. The correlation between platelet tests was only moderate in both scenarios

A presente tese teve como objetivo realizar a descrição dos microrganismos que já foram isolados ou detectados em infecções endodônticas de dentes decíduos em pacientes infantis por meio de uma revisão sistemática, além de avaliar a composição bacteriana e a presença de genes de resistência a antibióticos em amostras de saliva (S), biofilme supragengival (SB), dentina (D) e câmara pulpar (RC) de dentes decíduos com infecções endodônticas. No Capítulo 1, realizou-se revisão sistemática em bancos de dados eletrônicos, tendo sido incluídos estudos clínicos que avaliaram presença de microrganismos em dentes decíduos com infecções endodônticas, por meio de análise microbiológica com cultivo ou de métodos moleculares. Foi realizada análise descritiva dos dados. A análise identificou 44 títulos, sendo revisados, na íntegra, 17 artigos. Foram selecionados 8 estudos clínicos, de acordo com os critérios de inclusão determinados. Por meio de busca manual, foram selecionados 2 artigos adicionais, totalizando 11 artigos excluídos desta revisão. Nos oito estudos clínicos incluídos na revisão sistemática, a identificação dos microrganismos envolvidos nas infecções endodônticas foi realizada por meio de várias técnicas como: cultura microbiológica, hibridização DNA-DNA, PCR e suas variações, clonagem, sequenciamento e pirossequenciamento, confirmando a diversidade de microrganismos envolvidos nas infecções endodônticas de dentes decíduos. A análise dos dados sugere que as infecções endodônticas em dentes decíduos são causadas por múltiplas combinações de espécies de micro-organismos, confirmando a sua natureza polibacteriana. No Capítulo 2, amostras de S, SB, D e RC foram coletadas de pacientes infantis com infecções endodônticas. O perfil das comunidades microbianas foram obtidos por meio da análise da região espaçadora intergênica relacionada aos genes 16S e 23S rRNA (PCR-RISA). Determinaram-se e índices de riqueza, dominância, índice de Shannon, índice de Chao-1 (alfa-diversidade) e análise multivariada de conglomerados (método UPGMA e índice de Similaridade de Bray-Curtis) e análise de coordenadas principais (PCoA) (beta-diversidade). Há um baixo grau de agrupamento entre as amostras de S, BS, D e RC, obtidas de um mesmo participante. Se presentes, os agrupamentos acontecem para sítios contíguos, mas com baixo percentual de similaridade. Amostras de um mesmo ecossistema obtidas de diferentes participantes abrigam comunidades bacterianas distintas, com baixa similaridade. Não parece haver uma relação entre a presença de um sinal/sintoma clínico e acréscimo no perfil de similaridade das comunidades bacterianas em RC. Não foram observadas diferenças estatisticamente significativas entre os índices de alfa-diversidade (riqueza, dominância, Shannon e Chao-1) entre S, SB, D e RC. O uso prévio de antibióticos não modificou os resultados de alfa diversidade ou de beta diversidade obtidos. No Capítulo 3, verificou-se a distribuição dos genes de resistência bacteriana aos principais grupos de antibióticos em S, SB, D, e RC dentes decíduos em pacientes infantis com infecções endodônticas e também de amostras de saliva dos responsáveis (R) por meio de PCR para os genes cfxA/cfxA2, blaTEM, blaZ, ampC, mecA, mefA, ermB, ermC, tetQ, tetM, tetW, linB, lsaB. Realizou-se análise estatística descritiva e análise multivariada de conglomerados (método UPGMA e índice de Similaridade de Bray-Curtis). Dos pacientes selecionados, 3/8 utilizaram antibiótico previamente à coleta. Nenhum gene de resistência foi observado em todos os ecossistemas de um mesmo participante. Os genes mais frequentemente detectados foram os genes de resistência à tetraciclina tetQ e tetW. Não foram detectados nas amostras os genes ampC, mecA, lnuB e lsaB. A presença simultânea de um gene em dois nichos ocorre em ecossistemas contíguos. Não se observa um comportamento uniforme quanto ao perfil de agrupamento de diferentes amostras de um mesmo participante, e nem entre as amostras de saliva do participante infantil (S) e seu responsável (R). Há múltiplos perfis de distribuição de genes de resistência a agentes antimicrobianos em amostras de ecossistemas bucais contíguos em um mesmo paciente portador de infecção endodôntica. A análise conjunta dos dados permite concluir que cada um dos ecossistemas da cavidade bucal de crianças portadoras de infecções endodônticas avaliado apresenta espécies bacterianas e fatores de virulência distribuídos de forma única e distintas, a partir de uma perspectiva de análise de diversidade. / This thesis aimed assessing information on the bacteria that were isolated/detected in teeth with endodontic infections from infant patients through a sistematic review of the literature. Furthermore, the bacterial composition and the presence of resistance genes to antimicrobial agents was determined in saliva (S), in supragengival biofilm (SB), in dentine (D) and in pulp cavity (RC) samples. In the Chapter 1, a sistematic review was conducted in electronic databasis. Clinical studies that evaluated the presence of microorganims in primary teeth with endodontic infections through culture and molecular methods were included. Fourty-four titles were selected and 17 articles were fully revised. Eight clinical studies were selected for data extraction. Two articles were included following the hand search. According to the data analysis, microbial identification was performed by culture, DNA-DNA hybridization, PCR, cloning and sequencing and next-generation sequencing methods. A high diversity in the microbial components identificated/detected was reported. Endodontic infections in primary teeth are polymicrobial, with a multi-species consortia. In the Chapter 2, the S, SB, D and RC samples were collected from infanti patients with endodontic infections. The ribossomal intergenic spacer analysis (PCR-RISA) for the 16S-23S rRNA genes interspacer region was employed to determine the bacterial fingerprint for each sample. Metrics for alfa and beta diversity were employed, such as richness, dominance, Shannon Index, Chao-1 Index, cluster analysis (UPGMA, Bray-Curtis Index) and principal coordenate analysis (PCoA). There was a low grouping profile for shared samples of S, BS, D and RC from the same participant. When detected, clustering behavior was observed for contiguous sites, with low percentual of similarity between them. Samples from the same site but from different subjects harboured distinct bacterial communities, with low similarity. No clinical sign/symptom was detected as a grouping factor for RC sample from different subjects. No statistical difference was detected for the alfa-diversity indexes among S, SB, D and RC. The previous exposition to antimicrobial agentes has no effect over the alfa- and beta-diversity indexes. In the Chapter 3, the distribution of bacterial genes for antimicrobial resistance in S, SB, D and RC was determined in samples from children with endodontic infections and their relatives (R) by PCR. The presence of the genes cfxA/cfxA2, blaTEM, blaZ, ampC, mecA, mefA, ermB, ermC, tetQ, tetM, tetW, linB, and lsaB was detecte in the samples. Descriptive statistical analysis and multivariate anlysis (cluster analyisis, UPGMA and Bray-Curtis similarity index) were carried out. Three out of 8 patients had antimicrobial agents previously to the apointment. No resistance gene was shared by all envirnments in the same participant. The most frequently detected genes were tetQ and tetW. The genes ampC, mecA, lnuB, and lsaB were not detected in any the samples. The same gene was detected only in two contiguous niches. Clustering analysis revealed no grouping pattern among the samples, despite they were or not from the same participant or his/her relative. Multiple profiles of resistance genes distribution were detected in the oral cavity samples from infant participants. The oral cavity in children with endodontic infection is a complex environment that harbours unique bacterial communities profiles and a distinct distribution of resitance genes to antimicrobial agents, considering an ecological perspective.